A case of intraorbital malignant lymphoma biopsied using an endoscopic transnasal approach.
Biopsy
Endoscopic transnasal approach
Malignant lymphoma
Orbital tumor
Journal
Surgical neurology international
ISSN: 2229-5097
Titre abrégé: Surg Neurol Int
Pays: United States
ID NLM: 101535836
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
05
2023
accepted:
10
07
2023
medline:
10
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
While most orbital tumors are primary, some are secondary, including extension or invasion from adjacent sites. The diagnosis varies widely, and the treatment strategy depends on the pathological diagnosis. Transcranial and transorbital surgical approaches are typically used. Recently, a transnasal endoscopic approach has emerged as a viable option. We report a case of an intraorbital tumor treated with endoscopic transnasal biopsy and compare the results with those of other surgical approaches. A 74-year-old woman visited a nearby hospital due to a right eye protrusion and decreased visual acuity. An intraorbital tumor was detected and the patient was referred to our hospital. Head computed tomography revealed a mass along the posterior wall of the right orbital apex. Contrast-enhanced magnetic resonance imaging showed a 37-mm lesion with a uniform contrast effect and no intracranial extension. Intraorbital lymphoma was considered a differential diagnosis, and a biopsy was performed using an endoscopic transnasal approach. The pathological diagnosis was B-cell lymphoma, and chemotherapy was administered. The endoscopic transnasal approach for intraorbital tumors is less invasive, highly cosmetic, and useful, especially for medial and inferior orbital lesions.
Sections du résumé
Background
UNASSIGNED
While most orbital tumors are primary, some are secondary, including extension or invasion from adjacent sites. The diagnosis varies widely, and the treatment strategy depends on the pathological diagnosis. Transcranial and transorbital surgical approaches are typically used. Recently, a transnasal endoscopic approach has emerged as a viable option. We report a case of an intraorbital tumor treated with endoscopic transnasal biopsy and compare the results with those of other surgical approaches.
Case Description
UNASSIGNED
A 74-year-old woman visited a nearby hospital due to a right eye protrusion and decreased visual acuity. An intraorbital tumor was detected and the patient was referred to our hospital. Head computed tomography revealed a mass along the posterior wall of the right orbital apex. Contrast-enhanced magnetic resonance imaging showed a 37-mm lesion with a uniform contrast effect and no intracranial extension. Intraorbital lymphoma was considered a differential diagnosis, and a biopsy was performed using an endoscopic transnasal approach. The pathological diagnosis was B-cell lymphoma, and chemotherapy was administered.
Conclusion
UNASSIGNED
The endoscopic transnasal approach for intraorbital tumors is less invasive, highly cosmetic, and useful, especially for medial and inferior orbital lesions.
Identifiants
pubmed: 37560596
doi: 10.25259/SNI_404_2023
pii: 10.25259/SNI_404_2023
pmc: PMC10408611
doi:
Types de publication
Case Reports
Langues
eng
Pagination
259Informations de copyright
Copyright: © 2023 Surgical Neurology International.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Ophthalmology. 2004 May;111(5):997-1008
pubmed: 15121380
J Neurol Surg B Skull Base. 2015 Feb;76(1):12-24
pubmed: 25685644
Int Forum Allergy Rhinol. 2016 Feb;6(2):156-61
pubmed: 26623968
Neurosurgery. 2006 Jul;59(1 Suppl 1):ONSE159-60; discussion ONSE159-60
pubmed: 16888560
Ophthalmic Epidemiol. 2002 Feb;9(1):35-47
pubmed: 11815894
Eur Arch Otorhinolaryngol. 2012 Aug;269(8):1929-35
pubmed: 22237761
J Neurosurg. 2015 Sep;123(3):748-59
pubmed: 26052982
J Neurosurg. 2020 Jan 03;134(2):608-620
pubmed: 31899885
Acta Neurochir (Wien). 2008 May;150(5):441-5; discussion 445
pubmed: 18414776
Neurosurg Focus. 2007;23(5):E11
pubmed: 18004959
Front Oncol. 2022 Jan 03;11:780551
pubmed: 35047399